Department of Microbiology, Biochemistry and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA.
Department of Kriya Sharir, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP 221 005, India.
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314. doi: 10.1016/j.bbcan.2019.188314. Epub 2019 Nov 1.
Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth. Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor prognosis. Of all liver cancer cases, >90% are hepatocellular carcinomas (HCCs) for which chemotherapy and immunotherapy are the best options for therapy. For liver cancer patients, new treatment options are necessary. Use of natural compounds and/or nanotechnology may provide patients with better outcomes with lower systemic toxicity and fewer side effects. Improved treatments can lead to better prognoses. Finally, in this review, we present some of the problems and current treatment options contributing to the poor outcomes for patients with liver cancer.
在全球范围内,肝癌是最常见的致命恶性肿瘤;而在美国,肝癌的发病率排名第五。患者通常在肝癌晚期才被诊断出来,这导致了其预后较差。在所有肝癌病例中,超过 90%是肝细胞癌(HCC),化疗和免疫疗法是其最佳治疗选择。对于肝癌患者来说,需要新的治疗选择。使用天然化合物和/或纳米技术可能会为患者提供更好的结果,同时具有更低的全身毒性和更少的副作用。改进的治疗方法可以带来更好的预后。最后,在这篇综述中,我们介绍了一些导致肝癌患者预后不良的问题和当前的治疗选择。